<DOC>
	<DOCNO>NCT00876213</DOCNO>
	<brief_summary>The aim proposal dissect mechanism control gastric emptying , appetite food intake human , obtain new knowledge fight obesity pharmacological basis .</brief_summary>
	<brief_title>Amylin Glucagon-Like Peptide-1 ( GLP-1 ) : Influence Gastric Emptying , Appetite Food Intake Humans</brief_title>
	<detailed_description>The objective present study elucidate mechanism behind effect glucagon-like peptide-1 ( GLP-1 ) gastric empty , appetite food intake . The first GLP-1 base anti-diabetic therapy approve FDA 2005 market United States . The strong glucose-dependent insulinotropic property GLP-1 highly attractive feature pursue optimal glycaemic control type 2 diabetes . Moreover , potential GLP-1 reduce gastric emptying , appetite food intake make attractive tool fight obesity , pandemic condition often lead type 2 diabetes , several company develop weight lower drug base GLP-1 . Interestingly , another peptide , amylin , exert similar effect gastric emptying , appetite food intake human . Amylin find insulin-rich granule pancreatic beta-cells co-secreted insulin upon insulinotropic stimulus . Currently , know whether inhibit effect GLP-1 gastric emptying , appetite food intake directly mediate GLP-1 , effect secondary robust insulin response , thereby amylin response , elicit GLP-1 . The objective present study therefore elucidate mechanism effect order strengthen development anti-diabetic drug potential weight lower capability .</detailed_description>
	<mesh_term>Glucagon-Like Peptide 1</mesh_term>
	<mesh_term>Islet Amyloid Polypeptide</mesh_term>
	<criteria>Patients type 1 diabetes Informed oral write consent Caucasians age 18 year type 1 diabetes ( diagnose accord criterion WHO ) receive long acting insulin Cpeptide negative glucagon test Normal blood haemoglobin concentration Healthy control subject Informed oral write consent Caucasians age 18 year Normal 75 g oral glucose tolerance test ( OGTT ) accord criterion WHO Negative islet cell autoantibody ( ICA ) GAD65 autoantibodies No firstdegree relative diabetes Normal blood haemoglobin concentration Patients type 1 diabetes Residual betacell function ( evaluate glucagon test ) Impaired hepatic function ( aspartate aminotransferase ( ASAT ) and/or alanine aminotransferase ( ALAT ) &gt; 2 time upper normal limit ) Diabetic nephropathy ( serumcreatinine &gt; 130 µM and/or albuminuria ) Diabetic neuropathy Proliferative diabetic retinopathy Pregnancy , breastfeed intention become pregnant judge use inadequate contraceptive measure Healthy control subject Impaired hepatic function ( ASAT ALAT &gt; 2 time upper normal limit ) Impaired renal function ( serumcreatinine &gt; 130 μM and/or albuminuria ) Firstdegree relatives diabetes Pregnancy , breastfeed intention become pregnant judge use inadequate contraceptive measure</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>April 2009</verification_date>
	<keyword>Amylin</keyword>
	<keyword>GLP-1</keyword>
	<keyword>gastric empty</keyword>
	<keyword>appetite food intake</keyword>
</DOC>